INTRODUCTION
Over the past 10 years, the relationship between the mathematical description and biological determinants of hepatic drug clearance has been reasonably well defined and experimentally verified. These determinants include such factors as hepatic blood flow, the activity of the overall elimination process (intrinsic clearance), drug binding in the blood, and the anatomic arrangement of the hepatic circulation. On the other hand, integration of direct quantitative data and corresponding theory with respect to renal drug clearance is rather limited (1) (2) (3) (4) . In particular, the precise role of changes in plasma protein binding on the secretion kinetics of a drug is vague due to the complexity of renal excretion (4) (5) (6) (7) .
The proposed studies will systematically evaluate, using the isolated, perfused rat kidney, the effect of protein binding on the renal transport of furosemide. This diuretic represents a model compound in that it is highly plasma protein bound (>90%), demonstrates a net active secretion from the renal tubules, and is predominantly eliminated by the renal route in humans (8, 9) . In addition, furosemide is extensively used in various patient populations (10) (11) (12) and exerts its pharmacodynamic response from the luminal surface of the nephron (13) (14) (15) . Therefore, from a clinical as well as a mechanistic standpoint, it is important to determine whether protein binding is a limiting factor in furosemide secretion.
METHODS

Perfusate
The initial perfusate volume was 100ml (pH 7.4). It consisted of Krebs-Henseleit bicarbonate buffer (16) containing Fraction V bovine serum albumin (Miles Laboratories, Elkhart, IN), clinical-grade dextran (molecular weight 60,000-90,000; Sigma Chemical Co., St. Louis, MO), or a combination of the two, as well as glucose (0.1%), 14C-inulin (2.5/zCi, specific activity 2.0/zCi/mg; ICN Biomedicals, Irvine, CA), and eight L-amino acids (Sigma Chemical Co., St. Louis, MO) (17) .
Surgical Procedure
The development of the isolated, perfused rat kidney was based upon the methods of Nishiitsutsuji-Uwo et al. (18) and Bowman (19) . Male Sprague-Dawley rats (Charles River Breeding Laboratories, Wilmington, MA), 350-450 g, were anesthetized with sodium pentobarbital (-50 mg/kg). The left superficial femoral vein was exposed and 100 mg of mannitol and 200 units of heparin were administered. A midline incision was then made and the major abdominal blood vessels were isolated. A ligature was passed around the right renal artery, and distal and proximal ligatures were placed around the mesenteric artery. The right ureter was catheterized with PE-10 polyethylene tubing. The right renal artery was cannulated via the mesenteric artery and the hemostat holding back the perfusate was released just before the cannula entered the renal artery. The whole kidney was then excised, trimmed of adhering tissue, and immediately transferred to a recirculating perfusion apparatus, completely enclosed in a temperature-controlled (37~ Plexiglas chamber. Perfusion pressure in the renal artery was controlled by monitoring the manometer and adjusting the speed of the perfusion pump. A correction was made for the intrinsic apparatus pressure.
Experimental Design
Various combinations of bovine serum albumin (BSA) and dextran (D) were used in order to produce a wide range of values for the protein binding of furosemide. Two rats were studied at each particular combination (6.0% BSA+0% D; 4.0% BSA+l.33% D; 3.0% BSA+2.0% D; 2,0% BSA+2.67% D; 1.0% BSA+3.33% D; 0.5% BSA+3.67% D; 0.25% BSA+ 3.83% D; 0.08% BSA+3.94% D; 0.025% BSA+3.98% D; and 0% BSA+ 4.0% D) for a total of 20 experiments. The initial perfusate concentration of furosemide was 100 tzM.
After a 20-min equilibration period, furosemide was introduced as a bolus into the recirculating perfusate. An additional 20 rain was then allowed for drug distribution (2) . The subsequent experimental time was divided into 10-min urine collection periods for the measurement of kidney function and drug disposition parameters. The urine volume was measured with a tuberculin syringe and the pH was determined immediately. Perfusate (1.5 ml) was sampled at the midpoint time of each urine collection. The composition of recirculating perfusate was maintained by isovolumetric replacement of urine loss with buffer and perfusate sampling loss with perfusate (no drug present). Kidney function was determined by the fractional excretion of sodium and glucose, and by glomerular filtration rate (GFR). The renal clearance of inulin was taken to represent GFR. Renal clearances were calculated for furosemide and inulin by dividing the urinary excretion rate of the substance by its perfusate concentration at the midpoint time interval.
Analytical
Perfusate and urine samples containing furosemide were analyzed by a sensitive and specific HPLC assay developed by Smith et aL (20) , This method utilizes a direct injection technique where the only cleanup procedure involves the precipitation of albumin with acetonitrile. Representative urine samples were also analyzed for the glucuronide metabolite of furosemide and 2-amino-4-chloro-5-sulfamylanthranific acid (CSA), as described previously (20) . This is necessary since intrarenal metabolism can obscure the correct interpretation of renal clearance mechanisms (6) . These assays were modified to reflect the smaller volume requirement (0.05 ml) for perfusate and urine samples obtained during the isolated, perfused rat kidney experiments.
Radioactivity measurements for 14C-inulin were performed on an LS 9000 liquid scintillation counter (Beckman Instruments, Irvine, CA) using an external standard method for quench correction. Sodium was determined with a model 455 flame photometer (Corning Medical and Scientific, Medfield, MA) and glucose was determined colorimetrically using a commercial kit (Sigma Chemical Co., St. Louis, MO).
Protein Binding
The binding of furosemide to albumin in the recirculating perfusate was determined using an equilibrium dialysis method (20, 21) . One-half ml of perfusate was dialyzed against an equal volume of isotonic phosphate buffer (0.067 M, pH 7.4) at 37~ for 5 hr using Spectrapor 2 membrane tubing (Spectrum Medical Industries, Los Angeles, CA). Preliminary studies indicated that 5 hr was a sufficient amount of time for equilibrium to be reached at the various albumin concentrations employed in these experiments. Dialyzed buffer (0.3 ml) was then mixed with the internal standard, sodium phenobarbital, and injected into the HPLC system, as described previously (20) .
Furosemide exhibited a nonlinear binding in several experiments and values for percent free were determined accordingly (22, 23) . Since the initial volumes of the perfusate and buffer compartments were equal prior to dialysis, the volume-corrected bound concentration in the post dialysis perfusate (Cb") was calculated as Cb"= Cp-2. Cf' (1) where Cp represents the measured total plasma concentration of furosemide prior to dialysis and Cf' represents the measured unbound concentration of furosemide in buffer after dialysis. This equation was developed to correct for the osmotic water shift that occurs during equilibrium dialysis, resulting in lower protein and bound drug concentrations in the postdialysis plasma compartment (23 (2) and the relationship Cp = Cf+ Cb (22) . This results in the equation
in which Cf can be obtained by finding the positive root of the quadratic equation (3) for given values of Cp and BSA.
The percent of unbound furosemide in the original recirculating perfusate can now be determined by
Renal Transport Models
For a compound of low extraction (plasma flow to the kidney >> intrinsic renal tubular secretion), Levy (4) proposed the following models to express the relationship between renal drug clearance (CLr) and free fraction (fu):
where F represents the tubular reabsorption fraction, Ks the renal tubular secretion clearance referenced to unbound drug concentrations in plasma, and Ks' the renal tubular secretion clearance referenced to total drug concentrations in plasma. Both equations assume that renal tubular secretion remains linear over the concentration range studied and that the tubular reabsorption fraction is constant and involves the passive diffusion of nonionized drug molecules from the distal region of the renal tubules. Accordingly, if the rate of renal tubular secretion is a function of the unbound drug, then a plot of renal clearance versus free fraction in plasma should be linear and intersect the origin [Eq. (5)]. If the rate of renal tubular secretion is a function of the total drug, then a plot of renal clearance versus free fraction should be linear and have a positive intercept [Eq. (6)]. However, application of these relationships to furosemide revealed that Eqs. (5) and (6) were not appropriate to describe our data (see results). Therefore, the theoretical models below were derived.
In general, the excretion of a drug from the plasma into the urine is expressed by
where U is the drug concentration in urine, r~ is the urine flow rate, S is the rate of secretion, and A is the rate of reabsorption. By assuming that two Michaelis-Menten terms are needed to describe a drug's rate of active secretion, and that secretion is dependent upon free drug concentrations, we can express S and A by
where Vm~ and Krnl are the maximum velocity of secretion and the Michaelis constant, respectively, for the low-affinity, high-capacity transport system, and Vm2 and Kin2 are the maximum velocity of secretion and the Michaelis constant, respectively, for the high-affinity, low-capacity transport system. Therefore, the renal clearance becomes
The excretion ratio (ER) is then obtained by dividing each side of Eq.
Since the second transport system is of a high-affinity, low-capacity nature, Cf >> Kin2, and Eq. (11) simplifies to
Kml + Cf -~ " The urinary excretion rate (U. r~) was derived by substituting S [Eq. (8) ] and A [Eq. (9)] into Eq. (7) and then applying the same assumptions as in Eq. (12) (Cf>> Km2):
Experimental data were fitted to Eqs. (2), (12) , and (13) using the nonlinear least-squares regression program NONLIN (24) . The parameter estimates (+standard deviation) were obtained using a weighting factor of unity and the goodness of the fit was determined by R 2, COR, and by visual examination of the residuals. Table II .
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RESULTS
Physiological Function of the Perfnsed Kidney
Presented in Table I are the functional characteristics of perfusate experiments containing furosemide when carried out at various albumin/dextran combinations. Kidney function as reflected by GFR and fractional glucose excretion (FEglucose) were within the normal range of values for this technique (2, 3, 17, 25) , although a general reduction of GFR and perfusate flow was observed as dextran concentrations became greater. Since furosemide is a "loop-diuretic," a fractional sodium excretion (FEsodium) of 12-23% is to be expected (26) . Nevertheless, the proximal tubule retains considerable capacity for transport, as evidenced by the relatively low values for FEglucose in all experiments (1). Predrug functional parameters were 0.988ml/min (GFR), 7.55% (FEsodium), and 0.96% (FEglucose) at 6% BSA+0% D; and 0.722 ml/min (GFR), 7.97% (FEsodium), and 2.34% (FEglucose) at 0% BSA+4% D.
Protein Binding
Using the input values of Cb" as the dependent variable and BSA and Cf' as the two independent varibles, the binding parameters of Eq. (2) were estimated as P~ =0.44 (0.14), P2 = 2.92 (0.86)/~M, P3 =0.022 (0.013)/xM -1, and P4=0.00034 (0.00020) /zM -t (R2=0.980; COR=0.975). The parameter estimates and the application of Eqs. (3) and (4) allowed for the calculation of the percent unbound of furosemide in the original perfusate samples. Table II demonstrates that the percent unbound of furosemide could be manipulated from very low values (0.785%) to almost 90% free drug under the albumin/dextran concentrations employed.
Furosemide Metabolism
Using a specific HPLC assay, we were unable to detect a glucuronide metabolite of furosemide or CSA in any of the samples tested. This lack of biotransformation or degradation during the kidney perfusion experiments is in agreement with a similar study where at least 97% of the radioactivity present in perfusate or urine samples was reported as unchanged furosemide (2).
Furosemide Excretion
In Table III , clearance values have been corrected for GFR to take into account the varying functional capacity among kidney preparations. The corrected renal and secretion clearances of furosemide are observed Table If . Furosemide was present at an initial concentration of 100/.t M. Number of clearance periods studied in each group is shown in Table I . CLr/GFR represents the renal clearance of furosemide corrected for glomerular filtration rate. CLs/GFR represents the secretion clearance of furosemide corrected for glomerular filtration rate (CLs/GFR was calculated as CLr/GFRfu). CLr/(fu. GFR) represents the excretion ratio, which is the renal clearance of furosernide corrected for the fraction unbound in the perfusate and glomerular filtration rate.
to increase as the unbound fraction increases. However, they do so in a nonproportional manner, implying that the renal transport of furosemide may be complicated by a capacity-limited secretory component. This finding is further supported by the values for excretion ratio, which indicate a reduction in net secretion (from 60.8 to 8.72) as the fraction unbound becomes greater. Preliminary inspection of the data revealed that the renal mechanisms of furosemide transport may be even more complex (Figs. 1  and 2 ). Both Figs. 1 and 2 appear to have a prominent y intercept as well as a convex ascending curve. To be consistent with the underlying assumptions of Eq. (5) or (6), a plot of secretion clearance versus percent free would have to be a straight line with a zero y intercept or remain a constant Value, respectively. This led us to suspect that the renal tubular secretion of furosemide may involve two different transport mechanisms over the Tables II and III). concentration range studied. The experimental evidence in support of this hypothesis is presented below. The relationship between excretion ratio and unbound concentration of furosemide in the isolated, perfused rat kidney is shown in Fig. 3 (17.5 nmole/min) were calculated by multiplying P1 and P3 by the mean value for GFR (0.778 ml/min). As observed in Fig. 3 , the data are compatible with the proposed model in which furosemide secretion is described by two distinct transport processes.
The data were also fitted to Eq. (13), in which the relationship between urinary excretion rate and unbound concentration of furosemide in the isolated, perfused rat kidney was examined (Fig. 4) . Using the input values U. V and Cf and a mean value of 0.778 ml/min for GFR in the right side of the equation, we estimate the unknown parameters (Vm I as P~, Km~ as /2, and Vm2 as P3; F = 0; see discussion) as Vml = 300 (53.9) nmole/min, Kml = 39.8 (12.4)/~M, and Vm2 ----22.1 (2.7) nm01e/min (R 2 --0.937; CaR = 0.917). Application of Eq. (13) resulted in smaller coefficients of variation than Eq. (12) for P~ and/2, but not P3-These differences probably reflect the inherent bias produced by data transformation and consequently weighting. Still, both of these equations (12) and (13) of the renal transport parameters of furosemide and support the hypothesis that furosemide secretion may be operating by two different mechanisms. While an equivalent mathematical relationship can be derived for the high-affinity, low-capacity transport term in Eq. (12) or (13) when the driving force is total drug, this theory is inconsistent with the data recently reported by Hall and Rowland (2).
DISCUSSION
Utilizing the isolated, perfused rat kidney, Bowman (1) demonstrated that the ability of the renal secretory mechanism to extract 35S-labeled furosemide from the perfusate was closely related to the concentration of unbound drug. At a perfusate concentration of 500/zM furosemide, secretion of the drug was doubled when the albumin concentration was decreased from 7.5 to 5 g/100 ml (corresponding to a percent unbound of 2.19 and 3115, respectively). Secretion was again doubled when the albumin concentration was further decreased to 2.5 g/100ml (corresponding to a percent unbound of 9.4). Although these changes in net furosemide secretion are in the same direction as changes in percent unbound, they are not always of the same magnitude. Similar findings were reported by Koschier and Acara (3) when studying the transport of ~4C-labeled trichlorophenoxyace-tate (2,4,5-T) in the isolated, perfused rat kidney. These authors concluded that the secretion of 2,4,5-T appears to be hindered by plasma protein binding. At an initial perfusate concentration of 1.86/~ M, the 2,4,5-T/inulin clearance ratio increased over 300-fold [from 0.019 in BSA (6%) perfusate to 6.16 in dextran (4%) perfusate] when the percent free increased 150-fold (from 0.46 to 70.7). Again, a nonproportional change was observed between the extent of plasma protein binding and the renal clearance of 2,4,5-T, as was the case for furosemide. These findings may reflect the fact that perfusion experiments were performed with a limited number of free fraction values (1) or only at the extremes of protein binding (3) . Renal tubular secretion may also be exhibiting capacity-limited transport at the concentrations being studied (1) .
Recently, Hall and Rowland (2) reported data on the renal and secretion clearances of [14C]furosemide, referenced to total and unbound drug concentrations, in the isolated, perfused rat kidney. Using various combinations of albumin and dextran, these investigators observed a linear relationship between the renal clearance of furosemide and free fraction. Furthermore, when the fraction unbound was zero, the y intercept was not significantly different from zero. Their data are consistent with the model expressed by Eq. (5), and support the view that for drugs that are actively secreted and of low renal extraction, the renal and secretory clearances are directly proportional to the fraction unbound. As a result, the excretion ratio of furosemide, which averaged approximately 4.6, was relatively constant over the 28-fold range of free fraction values, indicating a linear secretory mechanism. Discrepancies between our study and that of Hall and Rowland (2) probably reflect the fact that different concentrations of furosemide were employed. In our study, initial perfusate samples contained 100/zM of furosemide, whereas very low and nonpharmacologic concentrations of furosemide (<5/zM) were perfused in the study by Hall and Rowland (2) . In addition, the latter study did not correct for the volume shifts that can occur during equilibrium dialysis (23) , thereby causing systematic errors in the furosemide free fraction. Although we show a similar dependence of renal drug transport on free concentrations of furosemide, our data were complicated by the presence of capacity-limited secretion and by the appearance of more than one secretory transport system.
As previously mentioned, we observed a general reduction in GFR and perfusate flow in our experiments at lower albumin concentrations. Bowman et al. (27) in perfused rat kidneys and Duarte et al. (28) in micropuncture experiments in the rat also showed a fall in GFR as furosemide reached the urine in pharmacologically significant concentrations. Although both investigators state that the reason for the decline in GFR is unclear, they suggest that it may be due to an increased intratubular pressure which develops after the drug-induced reduction in tubular sodium and fluid reabsorption. However, in our studies the fractional sodium excretion was relatively constant as a function of albumin concentration, making this an unlikely explanation for the observed attenuation in GFR.
Alternatively, it is possible that increasing amounts of urinary furosemide caused a redistribution ofintrarenal blood (perfusate) flow to the midcortical nephrons (29, 30) . This could result in a reduction in the number of functioning nephrons, since this region comprises only 30% of the total nephron population (31) . Nevertheless, clearance values (CLr/GFR, CLs/GFR, ER) were corrected for GFR to take into account the varying functionality between kidney preparations. This approach to the treatment of the data minimizes the chance of the two-component active secretory system being a result of declining renal function. Further support for the validity of our model (i.e., two different transport systems for active secretion) is afforded when the furosemide data of Bowman (1) are superimposed upon the computer-generated regression line of Eq. (12) . As shown in Fig. 5 , the curves are remarkably similar even though a different study design and assay method were employed during the perfusion experiments. It should be noted that either no change or an increase in GFR was observed by Bowman (1) as the percent albumin was reduced.
Previous studies by Hori and co-workers (32) (33) (34) demonstrated that the renal tubular secretion of phenolsulfonphthalein, sulfamethizole, sulfamethoxazole, cephalexin, and ampicillin correlates with unbound drug concentrations. Their data were best fitted to a model in which only one Michaelis-Menten term describes renal tubular transport, and secretion rate is dependent upon free concentrations of drug in the plasma:
Our results did not fit this model very well, as shown in Figs. 6 and 7. Using different initial estimates for the renal transport parameters, the computerfitted curves displayed a marked and systematic deviation from the data in addition to having greater values for the residual sum of squares (61,578 in Fig. 6A and 10,824 in Fig. 6B versus 8869 in Fig. 3 ; 8423 in Fig. 7 versus 6270 in Fig. 4) . The discrepancy between our study with furosemide and those of Hori and co-workers (32-34) may reflect the different drugs examined. However, the unbound concentrations in their studies ranged from approximately 30 to 1500/zM, a value where the influence of the high-affinity, low-capacity transport system is minimal at best. Therefore, they may have been unable to detect, if existent, this second transport system. Interpretation of the data is based on the assumption that the reabsorption fraction F remains constant during and between experiments. In our analysis of the furosemide data we assumed that F was equal to zero. This was done for several reasons. First, Bowman (1) demonstrated that in the presence and absence of albumin, probenecid reduced the renal clearance of furosemide to that expected from filtration alone. This suggests that the extent of furosemide reabsorption is minimal at best in the isolated, perfused rat kidney. Second, we also fitted our data to the transport models expressed by Eqs. (12) and (13) where F was allowed to be an unknown parameter. Regardless of the initial estimates provided, F was computed as zero. Third, at the urinary pH values observed in our studies (mean of 6.9; CV of 5.5%) and given that the pKa of furosemide is 3.9 (35), the fraction of total drug nonionized would be insignificant. These facts, plus the lack of either a urine flow or pH effect on furosemide renal clearance, indicate that in these experiments reabsorption is not a significant mechanism of renal transport for this drug (2) . The present study has attempted to integrate quantitative data with a corresponding model for the renal transport of furosemide. Our results demonstrate that the renal mechanisms of furosemide excretion are more complex than previously reported (1, 2) . Specifically, we show that the renal tubular secretion of furosemide may involve two different transport mechanisms over the concentration range studied. One secretory site is consistent with a high-affinity, low-capacity transport and the other with a low-affinity, high-capacity transport. Although speculative, these different transport mechanisms may reflect the morphological and functional heterogeneity of the proximal tubule cells (36, 37) .
